sorafenib has been researched along with licochalcone a in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (licochalcone a) | Trials (licochalcone a) | Recent Studies (post-2010) (licochalcone a) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 244 | 10 | 182 |
| Protein | Taxonomy | sorafenib (IC50) | licochalcone a (IC50) |
|---|---|---|---|
| Isocitrate dehydrogenase [NADP] cytoplasmic | Homo sapiens (human) | 5.176 | |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | 0.97 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.6543 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiu, YF; Hsieh, YH; Lin, CL; Lin, CY; Liu, CJ; Wu, MH; Wu, PL; Wu, WJ | 1 |
1 other study(ies) available for sorafenib and licochalcone a
| Article | Year |
|---|---|
Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Chalcones; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Humans; Liver Neoplasms; MAP Kinase Kinase 4; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mice, Nude; Sorafenib; Urokinase-Type Plasminogen Activator; Xenograft Model Antitumor Assays | 2018 |